- In April 2025, a systematic review and meta-analysis published in the Journal of Musculoskeletal Surgery & Research confirmed the efficacy of hip distraction (HD) using external fixators in the treatment of LCPD. Based on data from 17 studies involving 259 children, HD was shown to significantly improve hip range of motion (abduction +21°, flexion +24°), reduce pain, and enhance radiographic outcomes—suggesting HD as a promising minimally invasive option for late-stage LCPD
- In April 2024, Medivir AB—a pharmaceutical company dedicated to developing innovative cancer treatments in areas with significant unmet medical needs—announced that its selective cathepsin K inhibitor, MIV-711, received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from regulatory authorities for the treatment of Legg-Calvé-Perthes Disease (LCPD)
- In November 2023, the Scottish Rite for Children reported preclinical success with a BMP‑2–loaded hydrogel injection in adolescent models of LCPD. This breakthrough treatment accelerated bone repair in the necrotic femoral head, showing potential as a minimally invasive biologic therapy for pediatric patients
